Positive phase 2 data released on investigational lipid-lowering agent

Results from a recently completed phase 2 clinical trial demonstrate that a lipid-lowering molecule therapy had the ability to lower cholesterol by up to 43% and improve glycemic control among patients with type 2 diabetes, according to a press release.

“The results of our phase 2 study indicate that ETC-1002 could represent a major advance in our ability to regulate lipids in the treatment of patients with multiple cardiometabolic risk factors, especially in patients suffering from both dyslipidemia and diabetes. We look forward to advancing ETC-1002 to the final stages of development where we will evaluate its effects at higher doses in patients affected by dyslipidemia and diabetes,” Noah L. Rosenberg, MD, chief medical officer of Esperion Therapeutics, the developer of ETC-1002, told Endocrine Today.

The investigational, once-daily, oral molecule therapy has dual mechanism properties that enable it to potentially regulate imbalances in hepatic lipid and carbohydrate metabolism.

According to a press release, 60 patients with type 2 diabetes were administered ETC-1002 or placebo for 4 weeks in an inpatient facility. Researchers found that ETC-1002 significantly and consistently lowered LDL-C, with additional benefits to high-sensitivity C-reactive protein, glucose and other cardiometabolic risk factors.

The full data on these findings will be presented at a future scientific meeting, according to the press release. – by Samantha Costa